What is Sight Sciences' operating income?

Sight Sciences' total operating income in 2025 was -$37.10 million, based on the following breakdown: Total Gross Profit: $66.67 million Total Operating Expenses: $103.77 million

Sight Sciences (SGHT) Financials

$5.45 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$5.46 +0.00 (+0.09%)

As of 07/2/2026 04:10 PM Eastern

Compare

Annual Income Statements for Sight Sciences

This table shows Sight Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-35	-63	-86	-56	-52	-38
Consolidated Net Income / (Loss)	-35	-63	-86	-56	-52	-38
Net Income / (Loss) Continuing Operations	-35	-63	-86	-56	-52	-38
Total Pre-Tax Income	-35	-63	-86	-55	-51	-38
Total Operating Income	-32	-51	-84	-57	-51	-37
Total Gross Profit	18	40	59	69	68	67
Total Revenue	28	49	71	81	80	77
Operating Revenue	-	49	71	81	80	77
Total Cost of Revenue	9.21	8.61	12	12	12	11
Operating Cost of Revenue	-	8.61	12	12	12	11
Total Operating Expenses	51	92	143	126	119	104
Selling, General & Admin Expense	42	76	120	109	101	89
Research & Development Expense	8.87	16	23	18	18	15
Total Other Income / (Expense), net	-2.44	-11	-2.24	1.84	-0.74	-1.32
Interest Expense	2.40	4.37	4.47	5.41	6.62	5.14
Interest & Investment Income	0.03	0.00	0.00	7.29	5.92	3.97
Other Income / (Expense), net	-0.07	-6.93	2.23	-0.04	-0.03	-0.15
Income Tax Expense	0.06	0.19	0.05	0.11	0.24	0.01
Basic Earnings per Share	($3.71)	($2.36)	($1.80)	($1.14)	($1.03)	($0.74)
Weighted Average Basic Shares Outstanding	9.36M	26.73M	47.85M	48.63M	50.13M	52.15M
Diluted Earnings per Share	($3.71)	($2.36)	($1.80)	($1.14)	($1.03)	($0.74)
Weighted Average Diluted Shares Outstanding	9.36M	26.73M	47.85M	48.63M	50.13M	52.15M
Weighted Average Basic & Diluted Shares Outstanding	9.36M	26.73M	48.42M	49.55M	51.33M	54.01M

This table shows Sight Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-13	-11	-16	-12	-11	-12	-14	-12	-8.17	-4.16	-13
Consolidated Net Income / (Loss)	-13	-11	-16	-12	-11	-12	-14	-12	-8.17	-4.16	-13
Net Income / (Loss) Continuing Operations	-13	-11	-16	-12	-11	-12	-14	-12	-8.17	-4.16	-13
Total Pre-Tax Income	-13	-11	-16	-12	-11	-12	-14	-12	-8.25	-4.15	-13
Total Operating Income	-13	-11	-15	-13	-11	-12	-14	-12	-7.91	-3.67	-12
Total Gross Profit	17	16	16	18	17	17	15	17	17	18	17
Total Revenue	20	19	19	21	20	19	18	20	20	20	20
Operating Revenue	20	19	19	21	20	19	18	20	20	20	20
Total Cost of Revenue	2.68	2.78	2.79	3.03	3.25	2.51	2.41	2.98	2.71	2.60	2.72
Operating Cost of Revenue	2.68	2.78	2.79	3.03	3.25	2.51	2.41	2.98	2.71	2.60	2.72
Total Operating Expenses	31	27	31	31	28	28	29	28	25	21	29
Selling, General & Admin Expense	27	24	27	27	23	24	25	24	22	19	27
Research & Development Expense	4.24	3.43	4.64	4.32	4.75	4.29	4.43	4.39	3.35	2.44	2.55
Total Other Income / (Expense), net	0.45	0.43	-1.53	0.34	0.33	0.12	-0.25	-0.23	-0.34	-0.49	-0.56
Interest Expense	1.43	1.35	3.17	1.15	1.15	1.16	1.26	1.28	1.31	1.29	1.27
Interest & Investment Income	1.90	1.79	1.65	1.53	1.45	1.29	1.15	1.03	0.97	0.83	0.74
Other Income / (Expense), net	-0.01	-0.01	-0.01	-0.04	0.03	-0.01	-0.14	0.02	-0.00	-0.03	-0.03
Income Tax Expense	0.08	0.01	0.02	0.02	0.17	0.04	0.04	0.04	-0.08	0.01	0.01
Basic Earnings per Share	($0.27)	($0.22)	($0.33)	($0.25)	($0.22)	($0.23)	($0.28)	($0.23)	($0.16)	($0.07)	($0.24)
Weighted Average Basic Shares Outstanding	48.67M	48.63M	49.49M	49.90M	50.34M	50.13M	51.29M	51.82M	52.38M	52.15M	53.94M
Diluted Earnings per Share	($0.27)	($0.22)	($0.33)	($0.25)	($0.22)	($0.23)	($0.28)	($0.23)	($0.16)	($0.07)	($0.24)
Weighted Average Diluted Shares Outstanding	48.67M	48.63M	49.49M	49.90M	50.34M	50.13M	51.29M	51.82M	52.38M	52.15M	53.94M
Weighted Average Basic & Diluted Shares Outstanding	48.75M	49.55M	49.76M	50.31M	50.75M	51.33M	51.70M	52.37M	52.87M	54.01M	54.41M

This table details how cash moves in and out of Sight Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	40	199	-76	-47	-18	-28
Net Cash From Operating Activities	-32	-53	-76	-47	-22	-30
Net Cash From Continuing Operating Activities	-32	-53	-76	-47	-22	-30
Net Income / (Loss) Continuing Operations	-35	-63	-86	-56	-52	-38
Consolidated Net Income / (Loss)	-35	-63	-86	-56	-52	-38
Depreciation Expense	0.55	0.63	0.71	0.61	0.71	0.49
Amortization Expense	0.57	0.70	0.66	0.61	0.75	0.94
Non-Cash Adjustments To Reconcile Net Income	0.29	13	15	16	19	14
Changes in Operating Assets and Liabilities, net	0.78	-4.33	-5.70	-9.13	9.00	-6.40
Net Cash From Investing Activities	-0.95	-0.81	-0.97	-0.79	-0.39	-0.22
Net Cash From Continuing Investing Activities	-0.95	-0.81	-0.97	-0.79	-0.39	-0.22
Purchase of Property, Plant & Equipment	-0.95	-0.81	-0.97	-0.79	-0.39	-0.22
Net Cash From Financing Activities	73	253	1.25	1.10	4.96	1.79
Net Cash From Continuing Financing Activities	73	262	1.25	1.10	4.96	1.79
Repayment of Debt	-0.14	-	-	0.00	-36	0.00
Other Financing Activities, net	-0.01	4.86	1.25	1.10	41	1.79
Cash Interest Paid	1.29	3.11	3.25	4.27	4.26	4.19

This table details how cash moves in and out of Sight Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-10	-6.37	-11	-9.11	0.39	1.79	-12	-7.27	-8.86	-0.41	-7.00
Net Cash From Operating Activities	-9.83	-6.48	-9.79	-9.47	0.36	-3.46	-12	-7.54	-8.72	-1.83	-7.03
Net Cash From Continuing Operating Activities	-9.83	-6.48	-9.79	-9.47	0.36	-3.46	-12	-7.54	-8.72	-1.83	-7.03
Net Income / (Loss) Continuing Operations	-13	-11	-16	-12	-11	-12	-14	-12	-8.17	-4.16	-13
Consolidated Net Income / (Loss)	-13	-11	-16	-12	-11	-12	-14	-12	-8.17	-4.16	-13
Depreciation Expense	0.16	0.16	0.19	0.19	0.16	0.18	0.15	0.13	0.11	0.11	0.10
Amortization Expense	0.16	0.16	0.09	0.07	0.38	0.20	0.23	0.24	0.25	0.23	0.23
Non-Cash Adjustments To Reconcile Net Income	4.50	3.70	5.71	4.48	4.30	4.20	4.38	3.99	2.54	2.79	2.81
Changes in Operating Assets and Liabilities, net	-1.61	0.18	0.49	-1.89	6.59	3.81	-2.20	0.05	-3.44	-0.80	2.80
Net Cash From Investing Activities	-0.30	-0.26	-0.12	-0.08	-0.05	-0.14	0.00	-0.21	-0.17	0.16	-0.06
Net Cash From Continuing Investing Activities	-0.30	-0.26	-0.12	-0.08	-0.05	-0.14	0.00	-0.21	-0.17	0.16	-0.06
Purchase of Property, Plant & Equipment	-0.30	-0.26	-0.12	-0.08	-0.05	-0.14	0.00	-0.21	-0.17	0.16	-0.06
Net Cash From Financing Activities	0.12	0.38	-0.94	0.44	0.08	5.39	0.02	0.49	0.03	1.27	0.09
Net Cash From Continuing Financing Activities	0.12	0.38	-0.94	0.44	0.08	5.39	0.02	0.49	0.03	1.27	0.09
Repayment of Debt	-	-	-36	-	-	-	0.00	-	-	-	0.00
Other Financing Activities, net	0.12	0.38	35	0.44	0.08	5.39	0.02	0.49	0.03	1.27	0.09
Cash Interest Paid	1.10	1.10	1.05	0.97	1.00	1.24	1.04	1.05	1.06	1.05	1.04

This table presents Sight Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	73	280	213	167	143	115
Total Current Assets	71	277	210	163	140	113
Cash & Equivalents	62	261	185	138	120	92
Accounts Receivable	5.36	8.71	15	14	11	9.75
Inventories, net	2.60	3.48	6.11	7.85	6.33	7.77
Prepaid Expenses	1.16	4.16	3.42	2.60	2.31	3.26
Plant, Property, & Equipment, net	1.27	1.45	1.57	1.64	1.58	1.61
Total Noncurrent Assets	0.90	1.70	1.83	2.14	1.49	0.96
Other Noncurrent Operating Assets	0.90	1.70	1.83	2.14	1.49	0.96
Total Liabilities & Shareholders' Equity	73	280	213	167	143	115
Total Liabilities	44	48	53	46	55	51
Total Current Liabilities	9.31	14	18	12	15	11
Short-Term Debt	-	-	0.00	2.22	-	0.00
Accounts Payable	5.24	7.52	10	5.51	5.79	4.95
Current Employee Benefit Liabilities	4.07	5.99	7.35	4.53	9.68	6.07
Total Noncurrent Liabilities	35	35	35	34	40	40
Long-Term Debt	32	33	33	32	39	40
Other Noncurrent Operating Liabilities	3.06	1.92	1.87	2.48	0.49	0.03
Total Equity & Noncontrolling Interests	-89	232	160	120	88	64
Total Preferred & Common Equity	-89	232	160	120	88	64
Preferred Stock	-	-	0.00	0.00	0.00	0.00
Total Common Equity	-89	232	160	120	88	64
Common Stock	1.19	385	399	415	434	449
Retained Earnings	-90	-153	-239	-295	-346	-385
Other Equity Adjustments	-	-	-	-	-	0.00

This table presents Sight Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	177	156	150	144	130	122	116	110
Total Current Assets	174	152	146	140	127	119	114	107
Cash & Equivalents	145	127	118	119	109	102	92	85
Accounts Receivable	17	16	20	13	9.42	9.61	9.74	11
Inventories, net	9.24	6.87	6.78	6.09	5.81	6.21	7.98	7.01
Prepaid Expenses	2.90	2.29	1.45	2.89	2.91	2.10	3.49	3.95
Plant, Property, & Equipment, net	1.56	1.55	1.49	1.45	1.49	1.46	1.55	1.62
Total Noncurrent Assets	1.53	1.92	1.90	1.68	1.29	1.08	1.12	1.57
Other Noncurrent Operating Assets	1.53	1.92	1.90	1.68	1.29	1.08	1.12	1.57
Total Liabilities & Shareholders' Equity	177	156	150	144	130	122	116	110
Total Liabilities	50	46	48	49	52	52	52	56
Total Current Liabilities	14	12	13	14	12	12	12	18
Short-Term Debt	-	0.00	0.00	0.00	0.00	-	-	3.80
Accounts Payable	8.83	7.67	7.89	5.91	7.00	6.71	5.64	11
Current Employee Benefit Liabilities	5.50	4.03	5.39	7.89	5.13	5.23	6.19	3.69
Total Noncurrent Liabilities	35	35	35	35	40	40	40	38
Long-Term Debt	34	34	34	34	40	40	40	37
Other Noncurrent Operating Liabilities	1.48	0.96	1.02	0.69	0.35	0.20	0.07	0.90
Total Equity & Noncontrolling Interests	127	109	102	95	78	70	64	54
Total Preferred & Common Equity	127	109	102	95	78	70	64	54
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	127	109	102	95	78	70	64	54
Common Stock	411	420	425	429	438	442	445	452
Retained Earnings	-284	-311	-323	-334	-360	-372	-381	-398
Other Equity Adjustments	-	-	0.00	0.00	0.00	0.00	0.00	0.00

This table displays calculated financial ratios and metrics derived from Sight Sciences' official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
DEI Shares Outstanding	0.00	47,307,477.00	48,151,302.00	48,749,876.00	-	52,871,731.00
DEI Adjusted Shares Outstanding	0.00	47,307,477.00	48,151,302.00	48,749,876.00	-	52,871,731.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	-1.33	-1.79	-1.14	-	-0.73
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	77.12%	45.70%	13.63%	-1.47%	-3.13%
EBITDA Growth	0.00%	-83.33%	-40.81%	30.20%	12.46%	27.05%
EBIT Growth	0.00%	-81.05%	-39.93%	29.87%	11.78%	26.34%
NOPAT Growth	0.00%	-59.93%	-63.09%	31.78%	11.77%	26.58%
Net Income Growth	0.00%	-81.48%	-36.98%	35.59%	7.27%	25.40%
EPS Growth	0.00%	36.39%	23.73%	36.67%	9.65%	28.16%
Operating Cash Flow Growth	0.00%	-63.30%	-44.59%	37.89%	52.63%	-32.85%
Free Cash Flow Firm Growth	0.00%	0.00%	-53.17%	24.36%	45.76%	-22.58%
Invested Capital Growth	0.00%	479.52%	105.81%	90.88%	-59.27%	88.24%
Revenue Q/Q Growth	0.00%	0.00%	8.95%	-2.16%	0.40%	1.72%
EBITDA Q/Q Growth	0.00%	0.00%	-1.20%	7.53%	-19.60%	18.62%
EBIT Q/Q Growth	0.00%	0.00%	-1.13%	7.36%	-19.09%	18.11%
NOPAT Q/Q Growth	0.00%	0.00%	-2.86%	9.40%	-1.65%	18.21%
Net Income Q/Q Growth	0.00%	0.00%	-1.14%	10.06%	-2.29%	16.66%
EPS Q/Q Growth	0.00%	0.00%	-592.31%	10.24%	-0.98%	17.78%
Operating Cash Flow Q/Q Growth	0.00%	-4.31%	-6.71%	16.05%	11.92%	5.21%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	12.14%	10.78%	4.42%
Invested Capital Q/Q Growth	0.00%	0.00%	33.63%	-1.96%	-38.15%	2.43%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	66.68%	82.41%	82.67%	85.34%	85.50%	86.17%
EBITDA Margin	-112.63%	-116.58%	-112.66%	-69.20%	-61.48%	-46.30%
Operating Margin	-116.45%	-105.15%	-117.70%	-70.66%	-63.27%	-47.95%
EBIT Margin	-116.71%	-119.30%	-114.58%	-70.71%	-63.31%	-48.15%
Profit (Net Income) Margin	-125.52%	-128.61%	-120.90%	-68.53%	-64.49%	-49.67%
Tax Burden Percent	100.18%	100.30%	100.05%	100.20%	100.46%	100.03%
Interest Burden Percent	107.36%	107.48%	105.46%	96.72%	101.40%	103.14%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-2,400.71%	-942.93%	-328.59%	-313.93%	-276.28%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-2,379.80%	-928.45%	-316.51%	-296.51%	-257.50%
Return on Net Nonoperating Assets (RNNOA)	0.00%	2,352.38%	898.94%	288.96%	264.34%	225.54%
Return on Equity (ROE)	-121.81%	-48.32%	-43.98%	-39.64%	-49.59%	-50.74%
Cash Return on Invested Capital (CROIC)	0.00%	-1,010.42%	-1,012.13%	-391.08%	-229.70%	-337.51%
Operating Return on Assets (OROA)	-44.31%	-33.09%	-33.14%	-30.19%	-32.68%	-28.86%
Return on Assets (ROA)	-47.65%	-35.67%	-34.97%	-29.26%	-33.29%	-29.77%
Return on Common Equity (ROCE)	379.97%	-26.56%	-43.98%	-39.64%	-49.59%	-50.74%
Return on Equity Simple (ROE_SIMPLE)	39.05%	-27.13%	-53.88%	-46.21%	-58.85%	0.00%
Net Operating Profit after Tax (NOPAT)	-23	-36	-59	-40	-35	-26
NOPAT Margin	-81.52%	-73.61%	-82.39%	-49.46%	-44.29%	-33.57%
Net Nonoperating Expense Percent (NNEP)	-41.15%	-20.91%	-14.47%	-12.08%	-17.42%	-18.78%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-26.01%	-27.88%	-24.91%
Cost of Revenue to Revenue	33.32%	17.59%	17.33%	14.66%	14.50%	13.83%
SG&A Expenses to Revenue	151.03%	155.63%	168.32%	134.34%	126.24%	115.25%
R&D to Revenue	32.11%	31.93%	32.05%	21.66%	22.53%	18.88%
Operating Expenses to Revenue	183.14%	187.56%	200.37%	156.00%	148.77%	134.13%
Earnings before Interest and Taxes (EBIT)	-32	-58	-82	-57	-51	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-31	-57	-80	-56	-49	-36
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	3.58	3.67	2.09	2.11	6.56
Price to Tangible Book Value (P/TBV)	0.00	3.58	3.67	2.09	2.11	6.56
Price to Revenue (P/Rev)	6.06	16.98	8.24	3.10	2.31	5.42
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	147.98	52.00	9.20	15.91	29.94
Enterprise Value to Revenue (EV/Rev)	9.24	12.32	6.12	1.82	1.30	4.75
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	1.12	0.14	0.21	0.28	0.45	0.63
Long-Term Debt to Equity	1.12	0.14	0.21	0.26	0.45	0.63
Financial Leverage	-1.04	-0.99	-0.97	-0.91	-0.89	-0.88
Leverage Ratio	2.56	1.35	1.26	1.35	1.49	1.70
Compound Leverage Factor	2.74	1.46	1.33	1.31	1.51	1.76
Debt to Total Capital	52.87%	12.33%	17.23%	22.01%	31.02%	38.66%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	1.44%	0.00%	0.00%
Long-Term Debt to Total Capital	52.87%	12.33%	17.23%	20.57%	31.02%	38.66%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	194.14%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-147.01%	87.67%	82.77%	77.99%	68.98%	61.34%
Debt to EBITDA	-1.03	-0.57	-0.41	-0.60	-0.80	-1.13
Net Debt to EBITDA	0.95	4.00	1.89	1.86	1.65	1.44
Long-Term Debt to EBITDA	-1.03	-0.57	-0.41	-0.57	-0.80	-1.13
Debt to NOPAT	-1.42	-0.91	-0.57	-0.85	-1.11	-1.55
Net Debt to NOPAT	1.31	6.33	2.58	2.60	2.29	1.99
Long-Term Debt to NOPAT	-1.42	-0.91	-0.57	-0.79	-1.11	-1.55
Altman Z-Score	0.46	10.22	5.23	1.21	-0.96	0.89
Noncontrolling Interest Sharing Ratio	411.95%	45.03%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	7.58	20.52	11.77	13.29	9.04	10.22
Quick Ratio	7.18	19.95	11.23	12.44	8.48	9.22
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-41	-63	-48	-26	-32
Operating Cash Flow to CapEx	-3,376.08%	-6,462.48%	-7,831.44%	-5,965.11%	-5,805.45%	-13,256.25%
Free Cash Flow to Firm to Interest Expense	0.00	-9.43	-14.12	-8.82	-3.91	-6.17
Operating Cash Flow to Interest Expense	-13.39	-12.03	-17.01	-8.72	-3.37	-5.77
Operating Cash Flow Less CapEx to Interest Expense	-13.79	-12.22	-17.23	-8.87	-3.43	-5.82
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.38	0.28	0.29	0.43	0.52	0.60
Accounts Receivable Turnover	5.15	6.96	5.98	5.51	6.37	7.54
Inventory Turnover	3.54	2.84	2.58	1.70	1.63	1.52
Fixed Asset Turnover	21.78	35.96	47.16	50.49	49.61	48.50
Accounts Payable Turnover	1.76	1.35	1.37	1.49	2.05	1.99
Days Sales Outstanding (DSO)	70.82	52.46	61.04	66.28	57.30	48.43
Days Inventory Outstanding (DIO)	102.97	128.73	141.57	214.48	223.36	240.42
Days Payable Outstanding (DPO)	207.85	270.49	265.49	245.31	177.96	183.25
Cash Conversion Cycle (CCC)	-34.05	-89.30	-62.88	35.45	102.70	105.60
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	-1.07	4.08	8.39	16	6.52	12
Invested Capital Turnover	-25.74	32.62	11.45	6.64	7.09	8.23
Increase / (Decrease) in Invested Capital	0.00	5.15	4.31	7.62	-9.49	5.76
Enterprise Value (EV)	255	603	436	147	104	368
Market Capitalization	168	831	588	252	185	419
Book Value per Share	($9.50)	$4.91	$3.32	$2.47	$1.72	$1.21
Tangible Book Value per Share	($9.50)	$4.91	$3.32	$2.47	$1.72	$1.21
Total Capital	60	265	193	154	127	104
Total Debt	32	33	33	34	39	40
Total Long-Term Debt	32	33	33	32	39	40
Net Debt	-30	-228	-152	-104	-81	-52
Capital Expenditures (CapEx)	0.95	0.81	0.97	0.79	0.39	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.19	2.84	6.86	15	3.95	9.74
Debt-free Net Working Capital (DFNWC)	61	264	192	153	124	102
Net Working Capital (NWC)	61	264	192	151	124	102
Net Nonoperating Expense (NNE)	12	27	27	15	16	12
Net Nonoperating Obligations (NNO)	-30	-228	-152	-104	-81	-52
Total Depreciation and Amortization (D&A)	1.13	1.33	1.37	1.23	1.47	1.43
Debt-free, Cash-free Net Working Capital to Revenue	-0.69%	5.81%	9.62%	18.15%	4.94%	12.59%
Debt-free Net Working Capital to Revenue	221.85%	538.30%	268.97%	188.56%	155.64%	131.47%
Net Working Capital to Revenue	221.85%	538.30%	268.97%	185.82%	155.64%	131.47%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($2.36)	($1.80)	($1.14)	($1.03)	($0.74)
Adjusted Weighted Average Basic Shares Outstanding	0.00	47.59M	47.85M	48.63M	50.13M	52.15M
Adjusted Diluted Earnings per Share	$0.00	($2.36)	($1.80)	($1.14)	($1.03)	($0.74)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	47.59M	47.85M	48.63M	50.13M	52.15M
Adjusted Basic & Diluted Earnings per Share	$0.00	($2.36)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	26.73M	48.42M	49.55M	51.33M	54.01M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-36	-59	-40	-35	-26
Normalized NOPAT Margin	-81.52%	-73.61%	-82.39%	-49.46%	-44.29%	-33.57%
Pre Tax Income Margin	-125.30%	-128.22%	-120.84%	-68.39%	-64.20%	-49.66%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	-13.42	-13.38	-18.30	-10.60	-7.63	-7.24
NOPAT to Interest Expense	-9.38	-8.25	-13.16	-7.41	-5.34	-5.05
EBIT Less CapEx to Interest Expense	-13.82	-13.56	-18.52	-10.75	-7.69	-7.29
NOPAT Less CapEx to Interest Expense	-9.77	-8.44	-13.38	-7.56	-5.40	-5.09
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Sight Sciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	48,651,074.00	48,749,876.00	49,553,371.00	49,756,252.00	50,307,299.00	-	51,332,694.00	51,702,088.00	52,367,359.00	52,871,731.00	54,005,984.00
DEI Adjusted Shares Outstanding	48,651,074.00	48,749,876.00	49,553,371.00	49,756,252.00	50,307,299.00	-	51,332,694.00	51,702,088.00	52,367,359.00	52,871,731.00	54,005,984.00
DEI Earnings Per Adjusted Shares Outstanding	-0.27	-0.22	-0.33	-0.25	-0.22	-	-0.28	-0.23	-0.16	-0.08	-0.24
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.13%	-8.72%	2.34%	-8.95%	0.74%	1.72%	-9.12%	-8.45%	-1.25%	6.87%	12.51%
EBITDA Growth	36.77%	29.72%	16.49%	16.49%	18.63%	-7.02%	5.70%	9.28%	29.17%	70.92%	11.12%
EBIT Growth	36.33%	29.06%	16.24%	16.43%	16.53%	-7.34%	4.98%	8.29%	29.42%	69.01%	11.12%
NOPAT Growth	38.61%	34.86%	16.19%	16.70%	16.27%	-7.39%	5.87%	7.78%	29.60%	69.25%	10.43%
Net Income Growth	41.36%	36.77%	4.69%	16.44%	15.11%	-10.80%	12.98%	3.15%	26.18%	64.87%	8.29%
EPS Growth	41.30%	37.14%	5.71%	16.67%	18.52%	-4.55%	15.15%	8.00%	27.27%	69.57%	14.29%
Operating Cash Flow Growth	51.33%	58.17%	43.70%	29.81%	103.68%	46.65%	-18.59%	20.33%	-2,508.56%	47.18%	39.43%
Free Cash Flow Firm Growth	-33.33%	5.23%	28.00%	48.78%	89.34%	107.41%	81.22%	106.73%	-236.56%	-829.60%	-285.37%
Invested Capital Growth	160.16%	90.88%	25.00%	13.19%	-35.44%	-59.27%	-45.95%	-51.64%	13.67%	88.24%	12.21%
Revenue Q/Q Growth	-14.75%	-6.28%	2.74%	10.93%	-5.68%	-5.37%	-8.21%	11.74%	1.75%	2.41%	-3.37%
EBITDA Q/Q Growth	12.00%	17.60%	-33.77%	13.91%	14.25%	-8.37%	-17.87%	17.18%	33.05%	55.50%	-260.19%
EBIT Q/Q Growth	11.64%	17.16%	-32.48%	13.82%	11.75%	-6.53%	-17.29%	16.82%	32.09%	53.22%	-236.36%
NOPAT Q/Q Growth	11.69%	17.17%	-32.54%	14.07%	11.24%	-6.23%	-16.18%	15.82%	32.24%	53.60%	-238.41%
Net Income Q/Q Growth	11.65%	17.98%	-52.15%	24.20%	10.24%	-7.05%	-19.48%	15.64%	31.59%	49.05%	-211.87%
EPS Q/Q Growth	10.00%	18.52%	-50.00%	24.24%	12.00%	-4.55%	-21.74%	17.86%	30.43%	56.25%	-242.86%
Operating Cash Flow Q/Q Growth	27.14%	34.03%	-50.93%	3.25%	103.82%	-1,055.52%	-235.50%	35.00%	-15.59%	79.05%	-284.73%
Free Cash Flow Firm Q/Q Growth	8.32%	20.80%	12.79%	19.11%	80.92%	155.05%	-321.12%	128.99%	-1,053.97%	-19.33%	-16.79%
Invested Capital Q/Q Growth	7.29%	-1.96%	-2.44%	10.30%	-38.80%	-38.15%	29.45%	-1.30%	43.84%	2.43%	-22.83%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.62%	85.20%	85.50%	85.84%	83.88%	86.83%	86.21%	84.78%	86.39%	87.26%	86.19%
EBITDA Margin	-65.49%	-57.58%	-74.98%	-58.19%	-52.90%	-60.59%	-77.80%	-57.66%	-37.94%	-16.49%	-61.46%
Operating Margin	-67.02%	-59.24%	-76.42%	-59.20%	-55.71%	-62.54%	-79.16%	-59.64%	-39.71%	-17.99%	-63.02%
EBIT Margin	-67.08%	-59.30%	-76.47%	-59.41%	-55.58%	-62.57%	-79.95%	-59.51%	-39.72%	-18.15%	-63.16%
Profit (Net Income) Margin	-65.15%	-57.01%	-84.43%	-57.69%	-54.90%	-62.11%	-80.84%	-61.04%	-41.04%	-20.42%	-65.90%
Tax Burden Percent	100.60%	100.09%	100.10%	100.12%	101.52%	100.32%	100.29%	100.34%	99.04%	100.19%	100.08%
Interest Burden Percent	96.54%	96.06%	110.30%	97.00%	97.30%	98.94%	100.82%	102.22%	104.31%	112.30%	104.24%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-343.82%	-275.47%	-310.09%	-202.76%	-230.81%	-310.31%	-359.70%	-249.20%	-187.66%	-103.67%	-391.72%
ROIC Less NNEP Spread (ROIC-NNEP)	-341.19%	-273.19%	-304.85%	-199.38%	-227.52%	-306.53%	-354.23%	-244.03%	-183.81%	-101.26%	-384.16%
Return on Net Nonoperating Assets (RNNOA)	315.47%	249.41%	271.31%	172.16%	199.98%	273.28%	308.60%	207.69%	157.80%	88.70%	331.83%
Return on Equity (ROE)	-28.34%	-26.06%	-38.78%	-30.60%	-30.83%	-37.03%	-51.10%	-41.51%	-29.86%	-14.97%	-59.88%
Cash Return on Invested Capital (CROIC)	-480.36%	-391.08%	-293.20%	-236.23%	-215.86%	-229.70%	-229.28%	-197.00%	-294.64%	-337.51%	-290.09%
Operating Return on Assets (OROA)	-27.66%	-25.31%	-35.39%	-28.16%	-27.61%	-32.29%	-43.79%	-33.43%	-23.25%	-10.88%	-41.98%
Return on Assets (ROA)	-26.86%	-24.34%	-39.07%	-27.35%	-27.27%	-32.05%	-44.28%	-34.28%	-24.02%	-12.24%	-43.80%
Return on Common Equity (ROCE)	-28.34%	-26.06%	-38.78%	-30.60%	-30.83%	-37.03%	-51.10%	-41.51%	-29.86%	-14.97%	-59.88%
Return on Equity Simple (ROE_SIMPLE)	-48.61%	0.00%	-50.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-9.39	-7.78	-10	-8.86	-7.86	-8.35	-9.70	-8.17	-5.53	-2.57	-8.69
NOPAT Margin	-46.92%	-41.47%	-53.50%	-41.44%	-39.00%	-43.78%	-55.41%	-41.74%	-27.80%	-12.60%	-44.11%
Net Nonoperating Expense Percent (NNEP)	-2.63%	-2.28%	-5.24%	-3.38%	-3.29%	-3.78%	-5.47%	-5.17%	-3.86%	-2.40%	-7.55%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.04%	-7.21%	-6.54%	-6.09%	-6.58%	-8.28%	-7.44%	-5.30%	-2.46%	-9.20%
Cost of Revenue to Revenue	13.38%	14.80%	14.50%	14.16%	16.12%	13.18%	13.79%	15.22%	13.61%	12.74%	13.81%
SG&A Expenses to Revenue	132.46%	126.16%	137.86%	124.85%	116.04%	126.86%	140.07%	121.99%	109.26%	93.30%	136.28%
R&D to Revenue	21.19%	18.28%	24.06%	20.20%	23.55%	22.51%	25.30%	22.42%	16.84%	11.95%	12.93%
Operating Expenses to Revenue	153.65%	144.44%	161.93%	145.04%	139.58%	149.37%	165.37%	144.42%	126.10%	105.25%	149.21%
Earnings before Interest and Taxes (EBIT)	-13	-11	-15	-13	-11	-12	-14	-12	-7.91	-3.70	-12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-13	-11	-14	-12	-11	-12	-14	-11	-7.55	-3.36	-12
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.29	2.09	2.40	3.27	3.34	2.11	1.59	3.05	2.80	6.56	3.78
Price to Tangible Book Value (P/TBV)	1.29	2.09	2.40	3.27	3.34	2.11	1.59	3.05	2.80	6.56	3.78
Price to Revenue (P/Rev)	1.98	3.10	3.21	4.18	3.98	2.31	1.58	2.80	2.37	5.42	2.56
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	3.26	9.20	10.76	14.36	22.05	15.91	6.40	18.22	10.67	29.94	16.80
Enterprise Value to Revenue (EV/Rev)	0.64	1.82	2.06	3.12	2.92	1.30	0.69	1.99	1.68	4.75	2.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.27	0.28	0.31	0.33	0.36	0.45	0.51	0.57	0.62	0.63	0.75
Long-Term Debt to Equity	0.27	0.26	0.31	0.33	0.36	0.45	0.51	0.57	0.62	0.63	0.68
Financial Leverage	-0.92	-0.91	-0.89	-0.86	-0.88	-0.89	-0.87	-0.85	-0.86	-0.88	-0.86
Leverage Ratio	1.34	1.35	1.38	1.41	1.44	1.49	1.53	1.58	1.63	1.70	1.82
Compound Leverage Factor	1.29	1.30	1.52	1.37	1.40	1.47	1.54	1.62	1.70	1.91	1.90
Debt to Total Capital	20.99%	22.01%	23.58%	24.94%	26.45%	31.02%	33.77%	36.26%	38.40%	38.66%	42.92%
Short-Term Debt to Total Capital	0.00%	1.44%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	4.02%
Long-Term Debt to Total Capital	20.99%	20.57%	23.58%	24.94%	26.45%	31.02%	33.77%	36.26%	38.40%	38.66%	38.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	79.01%	77.99%	76.42%	75.06%	73.55%	68.98%	66.23%	63.74%	61.60%	61.34%	57.08%
Debt to EBITDA	-0.56	-0.60	-0.63	-0.67	-0.71	-0.80	-0.82	-0.85	-0.91	-1.13	-1.18
Net Debt to EBITDA	1.83	1.86	1.76	1.66	1.75	1.65	1.43	1.31	1.19	1.44	1.30
Long-Term Debt to EBITDA	-0.56	-0.57	-0.63	-0.67	-0.71	-0.80	-0.82	-0.85	-0.91	-1.13	-1.07
Debt to NOPAT	-0.76	-0.85	-0.88	-0.93	-0.98	-1.11	-1.14	-1.17	-1.26	-1.55	-1.62
Net Debt to NOPAT	2.50	2.60	2.46	2.32	2.43	2.29	1.99	1.81	1.65	1.99	1.78
Long-Term Debt to NOPAT	-0.76	-0.79	-0.88	-0.93	-0.98	-1.11	-1.14	-1.17	-1.26	-1.55	-1.47
Altman Z-Score	1.03	2.12	1.88	2.43	2.00	-0.06	-1.16	-0.44	-1.02	1.85	-1.57
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	12.11	13.29	13.01	11.01	10.18	9.04	10.47	10.01	9.60	10.22	5.86
Quick Ratio	11.26	12.44	12.22	10.39	9.53	8.48	9.75	9.31	8.63	9.22	5.26
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-19	-15	-13	-11	-2.07	1.14	-2.52	0.73	-6.97	-8.32	-9.72
Operating Cash Flow to CapEx	-3,232.89%	-2,456.06%	-8,364.10%	-11,835.00%	709.80%	-2,524.82%	0.00%	-3,591.90%	-5,128.82%	0.00%	-11,715.00%
Free Cash Flow to Firm to Interest Expense	-13.58	-11.40	-4.24	-9.49	-1.80	0.98	-2.00	0.57	-5.34	-6.46	-7.67
Operating Cash Flow to Interest Expense	-6.86	-4.80	-3.09	-8.27	0.31	-2.98	-9.19	-5.87	-6.68	-1.42	-5.54
Operating Cash Flow Less CapEx to Interest Expense	-7.08	-4.99	-3.13	-8.34	0.27	-3.09	-9.19	-6.04	-6.81	-1.30	-5.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.41	0.43	0.46	0.47	0.50	0.52	0.55	0.56	0.59	0.60	0.66
Accounts Receivable Turnover	5.61	5.51	5.09	4.18	5.33	6.37	6.23	5.17	6.71	7.54	7.95
Inventory Turnover	1.73	1.70	1.66	1.53	1.55	1.63	1.77	1.72	1.51	1.52	1.72
Fixed Asset Turnover	53.04	50.49	55.38	53.54	52.96	49.61	51.47	51.75	50.82	48.50	51.27
Accounts Payable Turnover	1.40	1.49	1.30	1.39	1.61	2.05	1.53	1.53	1.84	1.99	1.25
Days Sales Outstanding (DSO)	65.01	66.28	71.66	87.40	68.48	57.30	58.57	70.64	54.41	48.43	45.92
Days Inventory Outstanding (DIO)	210.94	214.48	219.91	237.85	236.25	223.36	206.51	212.62	242.03	240.42	212.50
Days Payable Outstanding (DPO)	260.43	245.31	280.23	262.77	227.14	177.96	238.87	238.93	198.60	183.25	293.11
Cash Conversion Cycle (CCC)	15.52	35.45	11.33	62.48	77.59	102.70	26.21	44.33	97.84	105.60	-34.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	16	16	16	17	11	6.52	8.44	8.33	12	12	9.47
Invested Capital Turnover	7.33	6.64	5.80	4.89	5.92	7.09	6.49	5.97	6.75	8.23	8.88
Increase / (Decrease) in Invested Capital	10	7.62	3.12	2.01	-5.79	-9.49	-7.18	-8.90	1.44	5.76	1.03
Enterprise Value (EV)	53	147	168	247	233	104	54	152	128	368	159
Market Capitalization	164	252	262	332	317	185	123	214	180	419	204
Book Value per Share	$2.61	$2.47	$2.20	$2.04	$1.89	$1.72	$1.51	$1.35	$1.23	$1.21	$1.00
Tangible Book Value per Share	$2.61	$2.47	$2.20	$2.04	$1.89	$1.72	$1.51	$1.35	$1.23	$1.21	$1.00
Total Capital	161	154	143	135	129	127	117	110	104	104	94
Total Debt	34	34	34	34	34	39	40	40	40	40	41
Total Long-Term Debt	34	32	34	34	34	39	40	40	40	40	37
Net Debt	-111	-104	-94	-84	-84	-81	-69	-62	-52	-52	-44
Capital Expenditures (CapEx)	0.30	0.26	0.12	0.08	0.05	0.14	0.00	0.21	0.17	-0.16	0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)	15	15	13	15	8.11	3.95	6.02	6.00	9.39	9.74	7.18
Debt-free Net Working Capital (DFNWC)	159	153	140	133	127	124	115	107	102	102	92
Net Working Capital (NWC)	159	151	140	133	127	124	115	107	102	102	88
Net Nonoperating Expense (NNE)	3.65	2.92	5.96	3.47	3.21	3.50	4.45	3.77	2.64	1.59	4.29
Net Nonoperating Obligations (NNO)	-111	-104	-94	-84	-84	-81	-69	-62	-52	-52	-44
Total Depreciation and Amortization (D&A)	0.32	0.32	0.29	0.26	0.54	0.38	0.38	0.36	0.35	0.34	0.34
Debt-free, Cash-free Net Working Capital to Revenue	17.78%	18.15%	16.09%	18.72%	10.19%	4.94%	7.70%	7.86%	12.35%	12.59%	9.03%
Debt-free Net Working Capital to Revenue	192.19%	188.56%	172.27%	167.57%	159.25%	155.64%	146.95%	140.88%	133.81%	131.47%	115.83%
Net Working Capital to Revenue	192.19%	185.82%	172.27%	167.57%	159.25%	155.64%	146.95%	140.88%	133.81%	131.47%	111.06%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.27)	($0.22)	($0.33)	($0.25)	($0.22)	($0.23)	($0.28)	($0.23)	($0.16)	($0.07)	($0.24)
Adjusted Weighted Average Basic Shares Outstanding	48.67M	48.63M	49.49M	49.90M	50.34M	50.13M	51.29M	51.82M	52.38M	52.15M	53.94M
Adjusted Diluted Earnings per Share	($0.27)	($0.22)	($0.33)	($0.25)	($0.22)	($0.23)	($0.28)	($0.23)	($0.16)	($0.07)	($0.24)
Adjusted Weighted Average Diluted Shares Outstanding	48.67M	48.63M	49.49M	49.90M	50.34M	50.13M	51.29M	51.82M	52.38M	52.15M	53.94M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.75M	49.55M	49.76M	50.31M	50.75M	51.33M	51.70M	52.37M	52.87M	54.01M	54.41M
Normalized Net Operating Profit after Tax (NOPAT)	-9.39	-7.78	-10	-8.86	-7.86	-8.35	-9.70	-8.17	-5.53	-2.57	-8.69
Normalized NOPAT Margin	-46.92%	-41.47%	-53.50%	-41.44%	-39.00%	-43.78%	-55.41%	-41.74%	-27.80%	-12.60%	-44.11%
Pre Tax Income Margin	-64.76%	-56.96%	-84.34%	-57.62%	-54.08%	-61.91%	-80.61%	-60.83%	-41.43%	-20.38%	-65.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-9.37	-8.23	-4.65	-11.09	-9.73	-10.27	-11.08	-9.07	-6.05	-2.87	-9.81
NOPAT to Interest Expense	-6.56	-5.76	-3.26	-7.73	-6.83	-7.19	-7.68	-6.36	-4.24	-1.99	-6.85
EBIT Less CapEx to Interest Expense	-9.59	-8.43	-4.69	-11.16	-9.78	-10.39	-11.08	-9.23	-6.18	-2.75	-9.86
NOPAT Less CapEx to Interest Expense	-6.77	-5.95	-3.29	-7.80	-6.87	-7.30	-7.68	-6.52	-4.37	-1.87	-6.90
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Sight Sciences (NASDAQ: SGHT) showed some operating improvement in Q1 2026, but the business remains unprofitable and is still burning cash. Revenue was essentially flat year over year, while operating losses and negative operating cash flow continued. The company does, however, still hold a sizeable cash balance and appears to have enough liquidity for now.

Cash balance remains strong: Sight Sciences ended Q1 2026 with $84.9 million in cash and equivalents, down from $92.4 million in Q3 2025 and $108.8 million in Q1 2025, but still a solid reserve.
Gross margin held up well: Q1 2026 gross profit was $17.0 million on $19.7 million of revenue, implying a gross margin of about 86%, which is healthy for a medical device business.
Operating loss improved versus a year ago: Operating loss narrowed to $12.4 million in Q1 2026 from $13.9 million in Q1 2025.
Cash burn improved sharply from prior quarters: Operating cash outflow was $7.0 million in Q1 2026 versus $11.6 million in Q1 2025 and $8.7 million in Q3 2025.
Revenue is holding near the $20 million quarterly level: Q1 2026 revenue of $19.7 million was close to Q4 2025 ($20.4 million) and Q3 2025 ($19.9 million), suggesting a relatively stable top line.
Quarterly revenue growth is modest: Q1 2026 revenue was down slightly from $20.4 million in Q4 2025 and $19.7 million in Q1 2025, so there is no clear acceleration yet.
Interest costs remain meaningful: Interest expense was $1.27 million in Q1 2026, while cash interest paid was $1.04 million, which continues to pressure profitability.
Balance sheet leverage is still notable: Long-term debt stood at $36.7 million at the end of Q1 2026, with total liabilities of $55.8 million.
Share count has crept higher: Weighted average basic shares rose to 53.9 million in Q1 2026 from 51.3 million in Q1 2025, which can dilute per-share results over time.
The company is still unprofitable: Q1 2026 net loss was $13.0 million, essentially in line with prior quarters and far from breakeven.
Operating expenses remain well above gross profit: SG&A was $26.8 million in Q1 2026, which alone exceeded total revenue and kept the company deeply loss-making.
Operating cash flow was negative: The company used $7.0 million in operating cash during the quarter, so it is still funding operations from its cash pile.
Cash and equivalents declined again: Cash fell from $92.4 million in Q3 2025 to $85.0 million in Q1 2026, continuing a multi-quarter downtrend.
Debt levels are elevated relative to equity value: With $36.7 million of long-term debt and just $53.9 million of common equity, the capital structure still looks strained for a company not yet generating profits.

Bottom line: Sight Sciences is showing some signs of stabilization, especially in gross profit and cash burn, but the core story has not changed much yet. Revenue is flat, losses persist, and the company is still consuming cash. For retail investors, the key question is whether management can turn modest revenue stability into real operating leverage before the cash balance erodes further.

07/05/26 07:48 AM ETAI Generated. May Contain Errors.

Sight Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Sight Sciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Sight Sciences' net income appears to be on a downward trend, with a most recent value of -$38.43 million in 2025, rising from -$34.69 million in 2020. The previous period was -$51.51 million in 2024. View Sight Sciences' forecast to see where analysts expect Sight Sciences to go next.

Sight Sciences' total operating income in 2025 was -$37.10 million, based on the following breakdown:

Total Gross Profit: $66.67 million
Total Operating Expenses: $103.77 million

Over the last 5 years, Sight Sciences' total revenue changed from $27.64 million in 2020 to $77.36 million in 2025, a change of 179.9%.

Sight Sciences' total liabilities were at $51.36 million at the end of 2025, a 7.2% decrease from 2024, and a 15.9% increase since 2020.

In the past 5 years, Sight Sciences' cash and equivalents has ranged from $61.51 million in 2020 to $260.69 million in 2021, and is currently $91.97 million as of their latest financial filing in 2025.

Over the last 5 years, Sight Sciences' book value per share changed from -9.50 in 2020 to 1.21 in 2025, a change of -112.7%.

Related Companies

Financial statements for NASDAQ:SGHT last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sight Sciences (SGHT) Financials

Financials Breakdown Chart

Key Financial Trends

Sight Sciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sight Sciences (SGHT) Financials

Annual Income Statements for Sight Sciences

Quarterly Income Statements for Sight Sciences

Annual Cash Flow Statements for Sight Sciences

Quarterly Cash Flow Statements for Sight Sciences

Annual Balance Sheets for Sight Sciences

Quarterly Balance Sheets for Sight Sciences

Annual Metrics And Ratios for Sight Sciences

Quarterly Metrics And Ratios for Sight Sciences

Financials Breakdown Chart

Key Financial Trends

Sight Sciences Financials - Frequently Asked Questions

When does Sight Sciences' fiscal year end?

How has Sight Sciences' net income changed over the last 5 years?

What is Sight Sciences' operating income?

How has Sight Sciences' revenue changed over the last 5 years?

How much debt does Sight Sciences have?

How much cash does Sight Sciences have?

How has Sight Sciences' book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools